Personalized medicine News
Most Popular Personalized medicine Story
Tysabri label change could add $1B to sales
Biogen Idec ($BIIB) has pulled off a big coup in personalized medicine. The multiple sclerosis drug Tysabri has long been weighed down by a well-known safety risk: It's linked with a potentially Read more...
Latest Headlines
- January 25, 2012
- January 23, 2012
- August 30, 2011
- April 12, 2011
- May 27, 2010
- March 29, 2010
- March 15, 2010
- March 11, 2010
- September 14, 2009
- August 20, 2009
- July 31, 2009
- July 20, 2009
- December 23, 2008
- July 24, 2008
- August 17, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
